News

Catalyst Pharmaceuticals and Lupin have settled a legal dispute related to Lupin’s generic version of Firdapse (amifampridine) — an approved brand-name treatment for Lambert-Eaton myasthenic syndrome (LEMS). Under the terms of the new deal, Lupin will not market its generic therapy in the U.S. prior to…

The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of more than 30 cancer centers across the U.S., has now included recommendations for testing for and managing Lambert-Eaton myasthenic syndrome (LEMS) in its updated guidelines for managing small cell lung cancer. While LEMS — an immune condition marked by…

Up to a year of treatment with Firdapse (amifampridine) was well tolerated, improved muscle strength, and eased symptoms in Japanese adults with Lambert-Eaton myasthenic syndrome (LEMS), a small clinical study shows. “This study revealed the long-term efficacy and tolerability of [Firdapse] in Japanese adults with LEMS,” the study’s…

Some people with Lambert–Eaton myasthenic syndrome (LEMS) experience a phenomenon called postexercise facilitation of reflexes, where normal reflexes are initially absent but then briefly return after a muscle is flexed. The case of a man who was diagnosed with LEMS after doctors noted postexercise facilitation of reflexes was…

A 56-year-old woman was diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) after having been earlier diagnosed with other autoimmune conditions, a U.K. case study reports. The woman’s previous conditions included neuromyelitis optica spectrum disorder (NMOSD), which primarily affects the spinal cord and optic nerve, which sends and receives signals…

In rare cases, Lambert-Eaton myasthenic syndrome (LEMS) may be associated with cancer of the esophagus, the tube that carries food down to the stomach, as highlighted in a recent case study. “This case emphasises the importance of diagnosing LEMS before tumour detection, maintaining suspicion for LEMS in atypical presentations,…

The U.S. Food and Drug Administration (FDA) has tentatively approved Lupin’s generic version of Firdapse (amifampridine) for people with Lambert-Eaton myasthenic syndrome (LEMS), ages 6 and older, according to a company press release. This means the treatment satisfies all the requirements to be marketed in the U.S.

Note: This story has been updated March 6, 2025, to correct a quote from Mindy Henderson, MDA vice president of disability outreach and empowerment. The Muscular Dystrophy Association (MDA) is once again hosting its annual gathering, the MDA Clinical & Scientific Conference. The 2025 event will take place…

Firdapse (amifampridine), an approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS), is now available to people in Japan with the rare autoimmune disease. The therapy, available in the form of 10 mg tablets, was launched by Dydo Pharma. Dydo is responsible for the development and commercialization…

An agreement between Catalyst Pharmaceuticals and Teva Pharmaceuticals has ended a U.S. patent litigation case that began when Teva applied to produce and market a generic version of Firdapse (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Under the terms of the settlement, announced…